(Q33155562)

English

Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Charles F. Levenback

5

object named as

Charles Levenback

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

Pedro T. Ramirez

1

object named as

Pedro T Ramirez

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

David Gershenson

7

object named as

David M Gershenson

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

author name string

Charles N Landen

2

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

Robert L Coleman

3

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

Michael R Milam

4

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

Taren A Johnston

6

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

language of work or name

0 references

publication date

1 October 2007

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

108

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

68-71

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.08.071

7 January 2021

Identifiers

10.1016/J.YGYNO.2007.08.071

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33155562&oldid=2034404557"